Campathecin

Camptothecin, a potent alkaloid found in the stem wood of the Chinese tree Camptotheca acuminata, displays remarkable selectivity in inhibiting the nuclear enzyme DNA topoisomerases, specifically Type I. Numerous semisynthetic derivatives derived from camptothecin have exhibited promising anticancer properties and have been studied extensively. These analogs have demonstrated notable activity against various tumor types.

＞98%

store at -20° C for one year（Powder）；
Store at a temperature of 2-4° C for a duration of two weeks in DMSO or any other suitable solvent. For a longer storage period of up to six months, it is recommended to store at a temperature of -20° C. Following these storage guidelines will ensure the stability and integrity of the solvent and its contents.

CPT

DMSO : 3 mg/mL (8.61 mM)

Topo I

The presence of DNA greatly enhances the efficacy of [3H]BrCPT labeling for topoisomerase I, whereas isolated DNA or topoisomerase I do not show significant labeling. Interestingly, camptothecin has an inhibitory effect on [3H]BrCPT labeling when DNA is present, indicating that BrCPT and CPT both bind to the same site on the DNA-topoisomerase I complex. Moreover, camptothecin induces nicking in closed circular pRR322 DNA (form I) in a concentration-dependent manner; this effect necessitates the presence of DNA topoisomerase I. Overall, these results suggest that both CPT and BrCPT modify the behavior of topoisomerase I via an interdependent mechanism involving DNA.

In an article published in Cancer Chemotherapy and Pharmacology in 2000, Peter Platzer, Theresia Thalhammer, Gerhard Hamilton, and their colleagues examined the metabolism of camptothecin, a potent inhibitor of topoisomerase I, in the isolated perfused rat liver. The study aimed to understand how the drug is processed by the liver and its potential impact on cancer treatment.
The researchers conducted experiments using an isolated perfused rat liver model, which allowed them to study the drug metabolism in a controlled environment. They administered camptothecin to the liver and monitored its conversion into metabolites.
The study revealed that camptothecin undergoes significant metabolism in the liver. The researchers identified various metabolites of camptothecin, shedding light on the breakdown pathways of the drug. These findings are crucial for understanding the pharmacokinetics of camptothecin and optimizing its therapeutic use.
The results also showed that the metabolism of camptothecin in the rat liver involves the activation of its lactone ring, leading to the formation of active metabolites. The active metabolites are known to inhibit the activity of topoisomerase I, an enzyme critical for DNA replication and repair. By understanding the metabolic pathways, researchers can gain insight into the effectiveness of camptothecin as a cancer treatment.
This study contributes to the growing body of research on camptothecin and its pharmacological properties. The findings provide valuable information for further investigations into the drug's mechanism of action and its potential use in clinical settings. Understanding how camptothecin is metabolized in the liver is essential for developing strategies to enhance its efficacy and minimize potential side effects.
Overall, the study by Platzer, Thalhammer, Hamilton, et al. highlights the importance of studying drug metabolism in the context of cancer treatment. By elucidating the metabolic pathways of camptothecin, researchers can pave the way for more targeted and effective therapies in the future.
[2].  Tanizawa A, Kohn KW, Kohlhagen G et al. Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives. Biochemistry. 1995 May 30;34(21):7200-6.
[3].  Slichenmyer WJ, Rowinsky EK, Donehower RC, Kaufmann SH. The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst. 1993 Feb 17;85(4):271-91.
[4].  Hertzberg RP, Busby RW, Caranfa MJ et al. Irreversible trapping of the DNA-topoisomerase I covalent complex. Affinity labeling of the camptothecin binding site. J Biol Chem. 1990 Nov 5;265(31):19287-95.
[5].  Hsiang YH, Hertzberg R, Hecht S, Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem. 1985 Nov 25;260(27):14873-8.